Good info about hoodia gordonii diet, I also tried it and was suprised with the reults I got, but I will have to work out a little more to keep the status quo
I read about hoodia diet a lot and found what Oprah had to say about hoodia in the O Magazine
also when I ordered to try out I did not pay for hoodia, I recommend you do not do it either untill you see if it works for you . You can find a list of free hoodia offers here
http://www.HoodiaWeightLossTrial.com
Approximately one person in 10 taking diet drug Acomplia (rimonabant) experiences psychiatric side effects and about one person in 100 experiences suicidal thoughts, according to U.K. regulators.
Of some 41,000 patients treated with rimonabant since it was launched in the U.K. in June 2006, 364 “psychiatric reactions have been reported,” the Department of Health’s Medicines and Healthcare Products Regulatory Agency (MHRA) said on July 19th.
“Amongst these, there have been 48 reports of depression, 16 reports of suicidal thoughts and one report of self-injury,” the regulatory agency said.
The MHRA said evidence suggested one person in 10 taking Acomplia may develop psychiatric side effects, and “approximately one patient in every 100 may experience suicidal thoughts.”
The MHRA advised: “If you start to experience symptoms of depression while taking Acomplia, or if you are currently being treated with antidepressants, consult your doctor.
“If you have had depression in the past but feel well on Acomplia, you should continue treatment with Acomplia and discuss your treatment with your doctor at your next routine appointment.”
The European Medicines Agency, however, took a more aggressive approach, deciding that Acomplia can remain on the market but with tougher warnings against its use by persons with major depression or anyone on an antidepressant.
The EMEA’s Committee for Medicinal Products for Human Use (CHMP) said “too many patients are taking Acomplia at the same time as antidepressants, even though Acomplia is not recommended for use in patients also taking antidepressants.”
While the CHMP said “Acomplia must no longer be used in these patients,” it concluded “that the benefits of Acomplia continue to outweigh its risks, except in patients with ongoing major depression or taking antidepressants.”
The European Medicines Agency (EMEA) recommended contraindicating Acomplia (rimonabant) from sanofi-aventis, in patients with ongoing major depression or who are being treated with antidepressants, because of the risk of psychiatric side effects. Doctors in the EU have already been warned about this since June 2006 but the Agency’s Committee for Medicinal Products for Human Use (CHMP) has now recommended upgrading this warning.
|
A new animal study on rimonabant (Acomplia / Zimulti) has identified yet one more possible health benefit for this controversial diet drug: it appears to reduce obesity-related liver damage that can lead to cirhossis of the liver. A team of researchers led by Mohammed Bensaid of Sanofi-Aventis, the company that has developed rimonabant, reported on these latest developments in the July 2007 issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases. In their study involving liver function in obese rats, the researchers said they found that rimonabant reduced markers of liver damage, decreased levels of pro-inflammatory proteins, and improved lipid profiles. Male obese rats were given rimonabant orally daily for 8 weeks and had their food intake monitored; control animals received the same amount of food as those receiving rimonabant. The researchers reported the results showed treatment with rimonabant reduced liver enlargement, completely abolished hepatic steatosis, and decreased blood levels of enzyme markers that indicate liver damage. It also strongly reduced levels of hepatic TNFa, a pro-inflammatory protein thought to induce insulin resistance in the liver and be involved in the progression of steatosis to hepatic fibrosis and cirrhosis. “Our hypothesis is that the multi-protective effects of rimonabant may be mediated for a large part by both the reduction in pro-inflammatory cytokines such as TNFa and the increase in anti-inflammatory and protective cytokines or hormones such as adiponectin,” the researchers said. “This suggests a potential clinical application for this CB1 receptor antagonist in the treatment of liver diseases associated with obesity and the metabolic syndrome,” they added. The researchers also emphasized that these results on Acomplia diet drug were not (or were only slightly observed) in the control animals eating the same diet but not given rimonabant, demonstrating the beneficial effects of the drug compared to diet alone. |
Buy Acomplia Rimonabant, a new class weight loss pill manufactured by French pharmaceutical Sanofi-Aventis. Rimonabant Acomplia works in a very unique way from other weight loss drugs like Xenical, hoodia or Reductil/Meridia and thus Acomplia Rimonabant (Zimulti) is most popular amongst all obese people.
In Acomplia drug, Rimonabant is the active ingredient which works on the principle of an appetite suppressant. The CB-receptors in the body are responsible for regulating food intake of the body. Usage of Acomplia (Rimonabant) basically obstructs the functioning of these CB-1 receptors, thereby decreasing your appetite. This activity in turn leads to weight loss. A combination of proper diet and regular workout regime along with Acomplia drug (Rimonabant) can pave path for an effectual weight loss.
Acomplia drug (Rimonabant) has been approved in the UK, Germany, Sweden, and Finland and USA as well by brand name Zimulti amid other countries with prescription. The benefits of Acomplia drug (Rimonabant) apart from weight loss can be accounted as improvements in the cardio metabolic risk factors, smoking cessation, minimization of chances of weight regain are to mention a few.
Rimonabant Acomplia (Zimulti) Dosage
Buy 20mg Acomplia diet pill, a customary dosage which should be taken with a glassful of water. Crushing or chewing Acomplia Rimonabant diet tablet may alter the chemical composition, and enhance the chances of unwanted side effects. Do not over indulge in Acomplia Rimonabant or Zimulti medication as it may harm your health. Strictly adhere to your doctors’ prescription for Acomplia Rimonabant dosage for effectual weight loss.
Buy Rimonabant Acomplia (Zimulti) online
You can buy Acomplia (Rimonabant) diet pill with the aid of online pharmacies. Online purchase can not only make it easier for you to buy Acomplia (Rimonabant) but also fetch you cheaper rates. Besides this, you can have your order delivered at your doorstep.
|
|
A new anti-obesity pill that has been shown to not only help lose weight and quit smoking could also be effective in helping people stop drug and alcohol addiction, scientists claim. Acomplia, or rimonabant, is an experimental drug developed by the French pharmaceutical firm Sanofi-Aventis primarily as a diet pill, but the drug works differently that most diet pills in that it blocks the brain’s reward system.
It works by blocking the connection between a pleasure-seeking activity, like smoking or overeating, and the reward “feeling” it causes in the brain. The human body contains endocannabinoids, marijuana-like substances that can stimulate the brain’s reward system.
Acomplia blocks the effect of the natural endocannabinoids by keeping them from attaching to the brain cells they usually stimulate, scientists say.
In March of this year, Acomplia gained a great deal of attention when two research studies demonstrated that it could not only help people lose weight, but quit smoking also. Last week, researchers reported rimonabant helped keep weight off for two years, lower bad cholesterol, increase good cholesterol, and it could possibly be used to fight drug and alcohol abuse.
Sanofi-Aventis will begin the process of seeking Food and Drug Administration approval for use of Acomplia in the United States. That process could begin as early as next year. Once the drug is approved for use as a diet pill in the U.S., it can then be studied for its effect on addicts and alcoholics, researchers say. However, the two-year study of Acomplia showed some side effects including depression, anxiety, and irritability. Researchers reported that those side effects were mostly minor and short-lived. But 13 percent of those in the trial who took the most effective dose of the drug, stopped taking it and dropped out of the study due to those side effects.
Some scientist have expressed concern about the mental side effects of the drug and some believe that the FDA will want to carefully study the long-rage use of the drug for possible risk factors before giving its approval, which could take years.
Background
Rimonabant (brand name Acomplia) has been pitched as the blockbuster weight loss drug of the decade. The company manufacturing the drug, Sanofi-Aventis believes that sales will reach $5.2 billion per year by 2010. That is a staggering amount of money.
Investors are getting swept up in the buzz, (rimonabant online),and desperate consumers are falling over themselves to get an opportunity to try the drug. However it is currently before the FDA awaiting approval - which some believe may come during early/mid 2006. Acomplia blocks cannabinoid (CB) receptors in the brain. The CB receptors are believed to play a role in controlling food consumption and dependence / habituation. People often refer to the cannabis-induced “munchies” or hunger pangs. Acomplia attempts to do the opposite.
In the scramble for profits and quick-fix obesity solutions - no one has bothered to raise questions about the long term side effects. It is up to the health authorities to determine what is an “acceptable risk” based on the data from the clinical trials conducted recently.
According to the results of the 1st year of clinical trials, patients taking the 20mg dosage of Rimonabant reported 50% more adverse events leading to discontinuation, than those in the placebo group. Of course Carol’s experiences must be kept in perspective - most people had no adverse side affects.
» Note the increase in psychiatric disorders as dosage increases
Is even one persons terrible experiences an “acceptable risk”? Maybe Acomplia will end up being prescribed to only the most “at-risk” obese patients - but who decides where that line lies?
You will not read about Carol’s experiences in any published paper. The data from the 2004 trial that Carol participated in has not (yet?) been made public. Sanofi funded the trial and holds the results.
Sanofi-Aventis “Because Health Matters”
2005 Worldwide Pharma Sales: 27,311 Million Euros (33 Billion USD).
100,000 employees worldwide (including a sales force of 33,000).
Present in more than 100 countries.
It is possible that Acomplia may be marketed as a Cardiovascular medication. US health insurers generally cover cardiovascular medication.
One pill for obesity and smoking– Rimonabant diet pill
Obesity is a major killer Use rimonabant |
Scientists are developing a pill that helps people quit smoking and slim down at the same time.
The drug, rimonabant, works by blocking the circuits in the brain that control the urge to eat and smoke.
Obesity and smoking have become two of the world’s biggest killers, and are being targeted for action in the UK.
The makers, French firm Sanofi-Synthelabo, hope to market rimonabant diet pill drug next year.
 |
Dr Robert Anthenelli |
In one trial the drug helped people to shed an average of 9kg (20lbs) in a year.
And in a second, it was found to double the chances of smokers successfully quitting - at least in the short term.
Dr Robert Anthenelli, of the University of Cincinnati, who directed the smoking study, said: “We think this might be the ideal compound for people who are overweight and smoke.”
Order Rimonabant online
Suicide risk fears over diet pill
The drug works by reducing appetite |
A weight loss drug used by thousands of Britons has been rejected by US safety officials because of an increased risk of suicide.
Rimonabant, launched in the UK last summer, has been shown to aid weight loss by reducing appetite.
But a committee advising the US Food and Drug Administration (FDA) voted to ban the pill, saying the manufacturers had failed to show it was safe.
European regulators will review the drug’s safety at an upcoming meeting.
Around 37,000 Britons have been prescribed rimonabant which can help users lose up to 10% of their body weight.
|
Dr Ian Campbell, Weight Concern |
The drug is currently recommended for obese patients with a risk of developing diabetes or cardiovascular disease.
It works by blocking receptors in the part of the brain that regulate food intake and the body’s ability to break down sugars and fats in the blood.
The National Institute of Clinical and Health Excellence (NICE) is currently appraising the drug for use on the NHS.
Safety concerns
The US committee of experts reviewed studies of rimonabant conducted around the world.
They told an FDA hearing that the drug is associated with an increased risk of suicidal thoughts even in those with no history of depression.
Studies had also highlighted significant increases in anxiety, insomnia, and panic attacks in patients given 20 mg of rimonabant compared with placebo.
A recent review of rimonabant by the Cochrane database concluded that more rigorous studies of efficacy and safety were required for a drug where the weight loss is “modest”.
Rimonabant Precautions - (Acomplia, Zimulti)
Do not consume Rimonabant (Acomplia, Zimulti) diet pill if you are allergic to any one of the ingredients.
The active substance is Rimonabant. Each film-coated tablet of Rimonabant (Acomplia, Zimulti) contains 20mg of rimonabant. The other ingredients are: Tablet Core: maize starch, lactose monohydrate, povidone K30 (E1201), croscarmellose sodium (E468), sodium laurilsulfate (E487), miceocrystalline cellulose (E 460), magnesium stearate.
Tablet coating: lactose monohydrate, hypromellose 15 mPa.s (E 464), titanium dioxide (E171), macrogol 3000.
Tablet polishing: carnauba wax (E 903)
It is advisable to stick to the prescribed Rimonabant dosage to attain the expected results. Pregnant women and breast-feeding mothers should avoid consumption of rimonabant, acomplia, or zimulti. Kindly inform your doctor about your medical history and any medication that you are taking, in order to avoid any contraindications of rimonabant diet pills .
Rimonabant should not be given to patients with hepatic or renal problems or with mental problems such as depression.
| Rimonabant News from July 2007 — News About Rimonabant | |
|
European Regulators Decide Diet Drug Rimonabant Should Remain on the Market
While diet drug rimonabant may double your risk of depression, its benefits “continue to outweigh its risks” for overweight and obese individuals who are not taking antidepressants, European drug regulators concluded on July 19th. But in deciding to let Acomplia remain on the market in Europe, the regulators expressed concern that “too many patients are taking Acomplia at the same time as antidepressants,” and issued a tougher warning to doctors to stop prescribing it to patients on antidepressants or suffering major depression. The European Medicines Agency (EMEA) issued their decision after reviewing safety data that led a U.S. FDA advisory panel last month to unanimously recommend against allowing rimonabant (also known as Zimulti) to be prescribed in the United States. The EMEA’s Committee for Medicinal Products for Human Use (CHMP) said it asked Sanofi-Aventis following the FDA advisory panel meeting in June 2007 to “submit all available information on the psychiatric side effects of Acomplia.” In assessing the data at its just concluded July meeting, the CHMP said it concluded “that the benefits of Acomplia continue to outweigh its risks, except in patients with ongoing major depression or taking antidepressants.” Acomplia is approved in Europe as an adjunct to diet and exercise for the treatment of obese or overweight adult patients. The EMEA said that while doctors were warned when rimonabant was approved a year ago that they ” should not prescribe Acomplia in patients with uncontrolled serious psychiatric conditions such as major depression,” the warning will now be upgraded. RImmonabant online |
